Abridge is a medical conversation AI startup that offers an audio-based system to record and summarize medical conversations. It was created for everyone, with a mission to help better understand their health conversations, whether at home or in the hospital.

Andes empowers microbes to enable positive action against climate change.

Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States.

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Braid Health is a digital health innovation company that develops an AI-powered diagnostic collaboration platform that improves the speed, quality, and workflow of radiologists and healthcare providers. Braid Health empowers radiologists and healthcare providers to deliver diagnoses for any patient, anywhere.

Bullseye Biosciences is a biotechnology research company based in Cambridge, MA. They specialize in the continuous evolution of biotherapeutics, unlocking the power of protein therapeutics. Their PRANCE platform combines robotics and phage assisted con...

Canaery is a neurotechnology and SaaS data company on a mission to introduce the world’s first enhanced working animals and unlock the hidden world of scent. By building a networked database of detectable odors, Canaery can revolutionize border and transportation security, medical screening and health diagnostics, and invasive pest inspections to make a safer, healthier society.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers and enables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials.

Democratizing gene therapy through transformative manufacturing methods

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.

Cypris Materials is developing a new generation of sustainable color that broadens the color gamut while simplifying manufacturing, application and formulation. Cypris Materials, Inc. has harnessed the transformative power of structural color - a method of producing color that has evolved over millions of years. Cypris Materials' structural coating platform helps industry-leading companies and individuals redefine the capabilities of color. Our polymers, backed by an extensive patent portfolio, unlock exclusive colors and effects that can only be achieved through our paint. Cypris’ materials enable a new paradigm: the first safe and sustainable structural color palette, free of toxic pigments and dyes.

Debut Biotech is a biotechnology company that focuses on providing specialty enzyme solutions combined with continuous manufacturing. It combines the power of enzymes with continuous manufacturing to create and modify small and large molecules for a wide range of industries and applications. The company was founded in 2019 and is based in San Diego, California.

Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois.

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill.

Elemental Machines’ Intelligent Operations Platform leverages the best of Internet of Things (IoT) technology and custom hardware/software solutions, delivering actionable insights to operators in life sciences, biopharma labs, biobanks, analytical labs, and manufacturing facilities. By connecting the physical and digital worlds, the platform simplifies, optimizes, and augments operations. Leaders in science, facilities, and technology trust Elemental Machines’ ecosystem for insights that accelerate innovation, predict outcomes, and shift from reactive to proactive management. With scalable solutions from incubator to enterprise, custom integrations to fit each operation’s unique needs, and a wide ecosystem of partnerships, Elemental Machines ensures operational excellence and the future-proofing of lab and manufacturing processes.

Elo is dedicated to improving human health and wellness through food by integrating technologies and enabling efficient food production systems.

EQUII is driven by the mission to fuel the body with nutritional and great tasting pantry essentials. Leveraging cutting edge science and our innovation in fermentation, we have unlocked a new way to create high protein grain flours with complete protein. Our unique fermentation process leverages the best qualities of wheat while converting extra starches into complete proteins using yeast in order to bring us essential amino acids that are critical to our health and activity. EQUII is nourishment that delights. Our protein is complete and highly digestible; meant to be enjoyed by everyone in the family. So gather around the table and enjoy EQUII together.

Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.